CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: As we reported previously [47], only 50% of pre-treated CD34+ CML stem/progenitor cells from IM-nonresponders responded to IM or DA treatment, and combination treatments of IM or DA with SNG inhibitors were significantly more effective (P < 0.02, Figure 4A).